Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

UGT1A1 Testing in Breast Cancer: should it become routine practice in patients treated with antibody-drug conjugates?

Critical reviews in oncology/hematology - 1 Apr 2024

Ibrahim Rebecca, Khoury Rita, Ibrahim Tony, Le Cesne Axel, Assi Tarek

Abstract excerpt

The use of genetic testing to personalize therapeutic strategies in cancer is rapidly evolving and thus changing the landscape of treatment of oncologic patients. The UGT1A1 gene is an important component for the metabolism and glucoronidation of certain drugs, including irinotecan and sacituzumab govitecan (SG); therefore, various UGT1A1 polymorphisms leading to decreased function of the UGT1A1 enzyme may lead...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Glucuronosyltransferase

Share to Immunoconjugates

Share to Irinotecan

Share to Quality of Life

Source

Identifiers

PMID: 38307394
DOI: 10.1016/j.critrevonc.2024.104265

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

UGT1A1 Testing in Breast Cancer: should it become routine practice in patients treated with antibody-drug conjugates?PMID 38307394Read ↗

Pre-Therapeutic UGT1A1 Genotyping in Breast Cancer Patients Receiving Sacituzumab Govitecan to Improve Safety: A Meta-Analysis and Recommendation.Semantic proximity Read ↗

UGT1A1 and Sacituzumab Govitecan Toxicity: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Pharmacogenetic approach for cancer treatment-tailored medicine in practice.Semantic proximity Read ↗

UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan.Semantic proximity Read ↗

Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.Semantic proximity Read ↗

Precision Medicine: UGT1A1 Genotyping to Better Manage Irinotecan-Induced Toxicity.Semantic proximity Read ↗

Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapySemantic proximity Read ↗

Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan.Semantic proximity Read ↗

Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.Semantic proximity Read ↗

Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer.Semantic proximity Read ↗

Pharmacogenetics and irinotecan therapy.Semantic proximity Read ↗

Pharmacogenetics of Irinotecan Disposition and Toxicity: A ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.